A clinician's view of voxelotor.

I Osunkwo, A Anderson, RC Brown… - British Journal of …, 2022 - search.ebscohost.com
In particular, diarrhoea occurred in 23% of patients receiving voxelotor 1500 mg in the
HOPE trial, more than double the frequency observed with placebo (11%). 19 Pro-active …
被引用次数：2 相关文章

[引用][C] A clinician's view of voxelotor.

I Osunkwo, A Anderson, RC Brown, N Shah… - British Journal of …, 2022 - europepmc.org
A clinician's view of voxelotor. - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

[引用][C] A clinician's view of voxelotor

I Osunkwo, A Anderson, RC Brown… - British Journal of …, 2022 - Wiley Online Library
Voxelotor is a first-in-class oral therapy designed to inhibit sickle haemoglobin (HbS)
polymerisation by increasing oxygen affinity for HbS. 1 Results from the pivotal …

[引用][C] A clinician's view of voxelotor

I Osunkwo, A Anderson, RC Brown… - British journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
A clinician's view of voxelotor A clinician's view of voxelotor Br J Haematol. 2022 Nov;199(4):616-618.
doi: 10.1111/bjh.18455. Epub 2022 Sep 16. Authors Ifeyinwa Osunkwo 1 , Alan Anderson 2 …